IP2M

IP2M (Innovation & Partnership for Personalized Medicine) is a French biotechnology company specializing in high-throughput genomic and transcriptomic analysis to support personalized medicine. Based in the Sophia Antipolis technology park, the company leverages advanced single-cell sequencing and bioinformatics to identify biomarkers and therapeutic targets for complex diseases. IP2M provides specialized R&D services to pharmaceutical companies and academic institutions, with a primary focus on oncology, respiratory health, and inflammatory conditions. By bridging the gap between academic research and clinical application, the company facilitates the development of precision diagnostics and tailored therapeutic strategies.